melatonin has been researched along with Delirium in 97 studies
Delirium: A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was no significant difference in the average proportion of delirium-free assessments per patient between the melatonin and placebo groups (79." | 9.51 | Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial. ( Anstey, M; Chapman, A; Ford, A; Hawkins, D; Ho, KM; Kelty, E; Litton, E; Martinez, FE; McCaffrey, J; Murray, K; Myers, E; Rashid, A; Regli, A; van Haren, FMP; Wibrow, B; Wyer, S, 2022) |
| "The current study (clinical trial registered number: CHWX-904-201511) suggests that acute melatonin treatment can reduce the incidence of delirium for elderly acute heart failure." | 9.51 | Effects of Melatonin for Delirium in Elderly Acute Heart Failure Patients: A Randomized, Single-Center, Double-Blind, and Placebo-Controlled Trial. ( Gu, L; Liu, X; Wan, R; Ye, T; Yin, B; Zong, G, 2022) |
| "Experimental evidence has indicated the benefits of melatonin (Mel) for the treatment of delirium." | 9.41 | Effects of Melatonin on Postoperative Delirium After PCI in Elderly Patients: A Randomized, Single-Center, Double-Blind, Placebo-Controlled Trial. ( Shi, Y, 2021) |
| "Although ramelteon has been examined as a relatively new therapeutic option for delirium prevention, current evidence to evaluate its efficacy is limited." | 9.41 | Ramelteon for delirium prevention in hospitalized patients: An updated meta-analysis and trial sequential analysis of randomized controlled trials. ( Carvalho, AF; Chang, CH; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yu, CL, 2023) |
| "To assess the efficacy of melatonin and melatonergic agonist for the treatment of delirium in hospitalized patients." | 9.41 | Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis. ( Beaucage-Charron, J; Coveney, R; Rinfret, J; Williamson, D, 2023) |
| "To determine the preventive effect of melatonin on delirium in the intensive care units." | 9.41 | Melatonin intervention to prevent delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. ( Bao, Q; Duan, Y; Shao, J; Wan, L; Wan, X; Wang, G; Yang, Y; Yue, J; Zhu, W, 2023) |
| "To determine the feasibility of a trial of oral melatonin 5 mg nightly for five nights for the treatment of delirium in older medical inpatients, and determine the participants required to demonstrate a clinically and statistically significant decrease in severity of delirium in older medical inpatients treated with melatonin." | 9.41 | Results from a double blinded, randomised, placebo-controlled, feasibility trial of melatonin for the treatment of delirium in older medical inpatients. ( Clayton-Chubb, DI; Lange, PW; Maier, AB; Watson, R, 2021) |
| "The 'Prophylactic Melatonin for Delirium in Intensive Care' study is a multi-centre, randomised, double-blinded, placebo-controlled trial." | 9.41 | Statistical analysis plan for the Prophylactic Melatonin for Delirium in Intensive Care (ProMEDIC): a randomised controlled trial. ( Anstey, M; Ford, A; Ho, KM; Kelty, E; Litton, E; Martinez, FE; Murray, K; Myers, E; Wibrow, B, 2021) |
| "Melatonin may be effective in reducing the severity of delirium after cardiac surgery." | 9.41 | Effect of Melatonin on Delirium After on-Pump Coronary Artery Bypass Graft Surgery: A Randomized Clinical Trial. ( Janatmakan, F; Javaherforoosh Zadeh, F; Jorairahmadi, S; Shafaeebejestan, E, 2021) |
| " Forty-two participants developed delirium, but it was evenly distributed between the groups (melatonin 21/98, 21." | 9.34 | The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium. ( Almeida, OP; Anstey, M; Edwards, M; Flicker, L; Ford, AH; Kelly, R; Passage, J; Patel, H; Wibrow, B, 2020) |
| "The Basel BOMP-AID study is an investigator-initiated, single-centre, randomised controlled clinical trial for the treatment of hypoactive delirium with the once daily oral administration of melatonin 4 mg versus placebo in 190 critically ill patients." | 9.34 | Study protocol for a prospective randomised double-blind placebo-controlled clinical trial investigating a Better Outcome with Melatonin compared to Placebo Administered to normalize sleep-wake cycle and treat hypoactive ICU Delirium: the Basel BOMP-AID s ( Abdelhamid, S; Cajochen, C; Gebhard, CE; Hollinger, A; Huber, J; Reinhold, S; Siegemund, M; Steiner, LA; Sutter, R; Todorov, A; Tran, F; von Felten, S, 2020) |
| " The respective melatonin (n = 30) vs placebo (n = 30) outcomes were: incident delirium in 11/30 (36." | 9.34 | Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. ( Agar, M; Bush, SH; Currow, DC; Dasgupta, M; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Pereira, JL; Tierney, S, 2020) |
| "In this randomized control trial, a total of 59 AOPP patients with subsequent delirium were randomly divided into two groups, the melatonin group (n=29) and the placebo-controlled group (n=30)." | 9.27 | Observation and analysis of clinical efficacy of melatonin on AOPP-induced delirium patients. ( Du, GH; Li, ZF; Pan, YY; Zhang, Y; Zhao, LB; Zhen, GD; Zhou, SZ, 2018) |
| "Studies suggest that melatonin may prevent delirium, a condition of acute brain dysfunction occurring in 20%-30% of hospitalized older adults that is associated with increased morbidity and mortality." | 9.27 | Melatonin and Sleep in Preventing Hospitalized Delirium: A Randomized Clinical Trial. ( Garcia, S; Jaiswal, SJ; Kang, DY; Loeks, M; Lu, CY; McCarthy, TJ; Owens, RL; Song, J; van Niekerk, CJ; Wineinger, NE, 2018) |
| "Although a previous review illustrated the efficacy of melatonin receptor agonists (MRAs) in preventing delirium, some recent randomized controlled trials (RCTs) did not confirm these effects." | 9.22 | Melatonin Receptor Agonists for the Prevention of Delirium: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Kawilapat, S; Kongsaengdao, S; Likhitsathian, S; Maneeton, B; Maneeton, N; Srisurapanont, M; Woottiluk, P, 2022) |
| "Studies on melatonin and melatonergic agents (MMA) for the prevention of postoperative delirium (POD) have produced inconsistent findings." | 9.22 | Melatonin and melatonergic agents for the prevention of postoperative delirium: A meta-analysis of randomized placebo-controlled trials. ( Wang, CM; Zhou, LY, 2022) |
| "The Healthy Heart-Mind trial is a randomized, double-blind, placebo-controlled clinical trial of 3 mg melatonin or matching placebo administered on seven consecutive days for the prevention of delirium following cardiac surgery." | 9.22 | The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial. ( Almeida, OP; Anstey, M; Edwards, M; Flicker, L; Ford, AH; Passage, J; Wibrow, B, 2016) |
| " Patients with or without delirium (as assessed using the Confusion Assessment Method for the ICU) were compared in terms of baseline characteristics and outcomes and the circadian rhythm of melatonin excretion using the 24-h excretion of its urinary metabolite 6-sulfatoxymelatonin (aMT6s)." | 9.20 | Delirium and Circadian Rhythm of Melatonin During Weaning From Mechanical Ventilation: An Ancillary Study of a Weaning Trial. ( Brochard, L; Brun-Buisson, C; Charles-Nelson, A; Dessap, AM; Katsahian, S; Launay, JM; Roche-Campo, F, 2015) |
| "To determine whether the postoperative administration of tryptophan would be beneficial for elderly adults undergoing surgery who are at risk of developing postoperative delirium." | 9.19 | Tryptophan supplementation and postoperative delirium--a randomized controlled trial. ( Adams, JC; Dunn, CL; Hawkins, CL; Moss, M; Raeburn, CD; Robinson, TN; Tran, ZV, 2014) |
| "In this older population with hip fracture, treatment with melatonin did not reduce the incidence of delirium." | 9.19 | Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. ( de Haan, RJ; de Jonghe, A; de Rooij, SE; Goslings, JC; Kloen, P; Levi, M; van Munster, BC; van Rees, C; van Velde, R; Wolvius, R, 2014) |
| ", melatonin) may have a role in the pathogenesis of delirium." | 9.15 | Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. ( Al-Aama, T; Brymer, C; Dasgupta, M; Esbaugh, J; Gutmanis, I; Woolmore-Goodwin, SM, 2011) |
| "Melatonin, a pineal gland hormone is reported to have a protective effect against delirium." | 9.12 | Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis. ( Khaing, K; Nair, BR, 2021) |
| " We reviewed the literature on the role of melatonin and ramelteon in the prevention of sleep disturbances and delirium in intensive care units and analysed the methods of melatonin therapy in an ICU setting." | 9.05 | The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit - a clinical review. ( Cubała, WJ; Lewandowska, K; Małkiewicz, MA; Mędrzycka-Dąbrowska, WA; Siemiński, M; Winklewski, PJ, 2020) |
| " Incidence of delirium was not significantly lower in patients who received melatonin, with an odd ratio, OR (95%Cl) of 0." | 9.05 | The effect of melatonin on delirium in hospitalised patients: A systematic review and meta-analyses with trial sequential analysis. ( Khor, AJ; Ng, KT; Teoh, WY, 2020) |
| " Studies reporting outcomes for melatonin or ramelteon use to prevent delirium in postoperative hospitalized patients (mean age ≥ 50 years) were eligible for inclusion." | 9.01 | Melatonin for the prevention of postoperative delirium in older adults: a systematic review and meta-analysis. ( Axon, DR; Campbell, AM; Lee, JK; Martin, JR; Mollon, L; Slack, MK, 2019) |
| "To investigate the efficacy of exogenous administration of melatonin and melatonin receptor agonists for the improvement of delirium, sleep, and other clinical outcomes of subjects in the intensive care unit (ICU)." | 9.01 | Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. ( Gao, F; Li, Z; Sun, W; Zhang, Q; Zhang, S, 2019) |
| "To review the prospective controlled trials available for the use of melatonin receptor agonists for delirium prevention." | 8.95 | Melatonin Receptor Agonists for Delirium Prevention. ( Gales, MA; Walker, CK, 2017) |
| "Recently, two high-quality clinical randomized controlled trials (RCTs) regarding the preventive effect of exogenous melatonin on delirium drew inconsistent conclusions." | 8.93 | Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials. ( Chen, S; Desislava, D; Liang, F; Shi, L; Wu, Q; Xu, L; Zhang, J, 2016) |
| "The objective of this review is to summarize the available data on the use of melatonin and melatonin agonist for the prevention and management of delirium in the elderly patients from randomized controlled trials (RCTs)." | 8.91 | Melatonin and melatonin agonist for delirium in the elderly patients. ( Chakraborti, D; Tampi, DJ; Tampi, RR, 2015) |
| " All papers on melatonin treatment in dementia were retrieved." | 8.86 | Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. ( de Jonghe, A; de Rooij, SE; Korevaar, JC; van Munster, BC, 2010) |
| "Consecutive patients admitted to the Tübingen University Stroke Unit, Tübingen, Germany, with acute ischemic stroke (AIS), who underwent standard care between August 2017 and December 2017, and patients who additionally received prophylactic melatonin (2 mg per day at night) within 24 h of symptom onset between August 2018 and December 2018 were included." | 8.02 | Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis. ( Boßelmann, C; Brendel, B; Fleischmann, R; Meisel, A; Mengel, A; Poli, S; Sartor-Pfeiffer, J; Stadler, V; Stefanou, MI; Ziemann, U; Zurloh, J, 2021) |
| "To compare the effect of prophylactic administration of melatonin, ramelteon, or no melatonin receptor agonist on the development of delirium in the intensive care unit (ICU)." | 8.02 | Evaluation of Delirium in Critically Ill Patients Prescribed Melatonin or Ramelteon. ( DeGrado, JR; Dube, KM; Lupi, KE; Romero, N, 2021) |
| "The development of ICU delirium was significantly lower in the melatonin group compared with that in the control group." | 7.91 | Effectiveness of Melatonin for the Prevention of Intensive Care Unit Delirium. ( Barnett, M; Baumgartner, L; Gross, K; Lai, J; Lam, K; Morris, A; Thompson, A, 2019) |
| "To assess if high morning plasma melatonin concentrations were associated with delirium." | 7.85 | Plasma melatonin levels in hip fracture patients with and without delirium: A confirmation study. ( de Rooij, SE; Kema, IP; Scholtens, RM; van Faassen, M; van Kempen, MF; van Munster, BC, 2017) |
| "Abnormalities in melatonin levels have been linked to delirium." | 7.85 | Role of Ramelteon in Reduction of As-Needed Antipsychotics in Elderly Patients with Delirium in a General Hospital Setting. ( Fazzari, M; James, SA; Lam, S; Pinkhasov, A; Singh, D, 2017) |
| "Preoperative CSF melatonin levels did not differ between patients with and without postoperative delirium." | 7.83 | Preoperative CSF Melatonin Concentrations and the Occurrence of Delirium in Older Hip Fracture Patients: A Preliminary Study. ( de Rooij, SE; Scholtens, RM; van Munster, BC; Vellekoop, AE; Vrouenraets, BC, 2016) |
| "To dynamic monitor and analyze the characteristic of polysomnography (PSG) and melatonin levels of delirium patients in intensive care unit (ICU)." | 7.80 | [Research of 24-hour dynamic sleep monitoring and melatonin changes in patients with delirium in intensive care unit]. ( Han, F; Liu, J; Sun, T; Sun, Y; Wang, X; Yang, J, 2014) |
| "We conducted a prospective observational study to assess the association of perioperative alteration of plasma melatonin concentration with delirium in 40 postoperative patients who required intensive care for more than 48 hours." | 7.79 | Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium. ( Egi, M; Kanazawa, T; Morimatsu, H; Morita, K; Toda, Y; Yoshitaka, S, 2013) |
| "All patients without delirium showed nearly identical preoperative and postoperative melatonin secretion for 24 hours, although peak values were significantly lower in patients more than 80 years old (7." | 7.71 | Postoperative delirium and melatonin levels in elderly patients. ( Ikeda, K; Kageyama, M; Machida, N; Menjo, M; Miura, M; Nimura, Y; Shigeta, H; Yasui, A, 2001) |
| "Delirium is highly prevalent in the intensive care unit (ICU) and is associated with adverse clinical outcomes." | 6.84 | Feasibility of melatonin for prevention of delirium in critically ill patients: a protocol for a multicentre, randomised, placebo-controlled study. ( Azad, A; Bernard, F; Burry, L; Detsky, M; Fan, E; Foster, J; Guenette, M; Mehta, S; Rose, L; Scales, D; Williamson, D, 2017) |
| "Melatonin is a naturally occurring, safe and cheap hormone that can be administered to improve sleep." | 6.84 | Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial. ( Anstey, M; Choo, L; Ford, A; Hardie, M; Hensley, M; Hillman, D; Kelty, E; Martinez, FE; Murray, K; Palmer, R; Roberts, B; Singh, B; Wibrow, B, 2017) |
| "Delirium is a frequent, costly and morbid problem." | 6.82 | Moderate dose melatonin for the abatement and treatment of delirium in elderly general medical inpatients: study protocol of a placebo controlled, randomised, double blind trial. ( Clayton-Chubb, DI; Lange, PW, 2016) |
| "Melatonin plays an important role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism of melatonin might play an important role in the development of delirium." | 6.76 | The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial. ( de Jonghe, A; de Rooij, SE; Goslings, JC; Kloen, P; Korevaar, JC; Levi, MM; van Munster, BC; van Oosten, HE; van Rees, C; van Velde, R; Wolvius, R, 2011) |
| "Melatonin levels have been shown to decline with aging." | 6.53 | Melatonin based therapies for delirium and dementia. ( Alagiakrishnan, K, 2016) |
| "Melatonin has a major role in control of circadian rhythm and sleep regulation and other effects on the immune system, neuroprotection, and oxidant/anti-oxidant activity." | 6.48 | Potential use of melatonin in sleep and delirium in the critically ill. ( Bellapart, J; Boots, R, 2012) |
| "Melatonin has been suggested as a low-risk pharmacological intervention to help prevent POD." | 5.72 | Melatonin for the prevention of postoperative delirium in older adults: a protocol for a systematic review and meta-analysis. ( Armstrong, RA; Barnes, J; Gibbison, B; Hinchliffe, R; Mouton, R; Pufulete, M; Sewart, E, 2022) |
| "Postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) are the most common central nervous system dysfunctions during the perioperative period." | 5.62 | Relationship among melatonin, postoperative delirium, and postoperative cognitive dysfunction. ( Mu, S; Wu, A; Wu, Y, 2021) |
| " There was no significant difference in the average proportion of delirium-free assessments per patient between the melatonin and placebo groups (79." | 5.51 | Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial. ( Anstey, M; Chapman, A; Ford, A; Hawkins, D; Ho, KM; Kelty, E; Litton, E; Martinez, FE; McCaffrey, J; Murray, K; Myers, E; Rashid, A; Regli, A; van Haren, FMP; Wibrow, B; Wyer, S, 2022) |
| "The current study (clinical trial registered number: CHWX-904-201511) suggests that acute melatonin treatment can reduce the incidence of delirium for elderly acute heart failure." | 5.51 | Effects of Melatonin for Delirium in Elderly Acute Heart Failure Patients: A Randomized, Single-Center, Double-Blind, and Placebo-Controlled Trial. ( Gu, L; Liu, X; Wan, R; Ye, T; Yin, B; Zong, G, 2022) |
| "Both insomnia and its treatment can lead to the development of delirium in older adults." | 5.48 | Delirium associated with only one dose of zopiclone in an older adult. ( Isik, AT; Kalan, U; Soysal, P, 2018) |
| "Delirium is a syndrome characterized by acute fluctuations and alterations in attention and arousal." | 5.43 | Melatonin and melatonin agonists to prevent and treat delirium in critical illness: a systematic review protocol. ( Burry, LD; Cheung, A; Chimunda, T; Choong, K; Duffett, M; Foster, J; Guenette, M; Menon, K; Rose, L; Thabane, L, 2016) |
| "Delirium is an acute-onset syndrome that exacerbates patients' condition and significantly increases consequential morbidity and mortality." | 5.42 | The diurnal profile of melatonin during delirium in elderly patients--preliminary results. ( Grodzicki, T; Klich-Rączka, A; Pac, A; Piotrowicz, K; Zdzienicka, A, 2015) |
| "Experimental evidence has indicated the benefits of melatonin (Mel) for the treatment of delirium." | 5.41 | Effects of Melatonin on Postoperative Delirium After PCI in Elderly Patients: A Randomized, Single-Center, Double-Blind, Placebo-Controlled Trial. ( Shi, Y, 2021) |
| "Although ramelteon has been examined as a relatively new therapeutic option for delirium prevention, current evidence to evaluate its efficacy is limited." | 5.41 | Ramelteon for delirium prevention in hospitalized patients: An updated meta-analysis and trial sequential analysis of randomized controlled trials. ( Carvalho, AF; Chang, CH; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yu, CL, 2023) |
| "To assess the efficacy of melatonin and melatonergic agonist for the treatment of delirium in hospitalized patients." | 5.41 | Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis. ( Beaucage-Charron, J; Coveney, R; Rinfret, J; Williamson, D, 2023) |
| "To determine the preventive effect of melatonin on delirium in the intensive care units." | 5.41 | Melatonin intervention to prevent delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. ( Bao, Q; Duan, Y; Shao, J; Wan, L; Wan, X; Wang, G; Yang, Y; Yue, J; Zhu, W, 2023) |
| "To determine the feasibility of a trial of oral melatonin 5 mg nightly for five nights for the treatment of delirium in older medical inpatients, and determine the participants required to demonstrate a clinically and statistically significant decrease in severity of delirium in older medical inpatients treated with melatonin." | 5.41 | Results from a double blinded, randomised, placebo-controlled, feasibility trial of melatonin for the treatment of delirium in older medical inpatients. ( Clayton-Chubb, DI; Lange, PW; Maier, AB; Watson, R, 2021) |
| "The 'Prophylactic Melatonin for Delirium in Intensive Care' study is a multi-centre, randomised, double-blinded, placebo-controlled trial." | 5.41 | Statistical analysis plan for the Prophylactic Melatonin for Delirium in Intensive Care (ProMEDIC): a randomised controlled trial. ( Anstey, M; Ford, A; Ho, KM; Kelty, E; Litton, E; Martinez, FE; Murray, K; Myers, E; Wibrow, B, 2021) |
| "Melatonin may be effective in reducing the severity of delirium after cardiac surgery." | 5.41 | Effect of Melatonin on Delirium After on-Pump Coronary Artery Bypass Graft Surgery: A Randomized Clinical Trial. ( Janatmakan, F; Javaherforoosh Zadeh, F; Jorairahmadi, S; Shafaeebejestan, E, 2021) |
| "Melatonin has a key role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism of melatonin might play an important role in the development of delirium." | 5.38 | [Delirium, insomnia in hospitalization and ramelteon]. ( Ito, T, 2012) |
| "Delirium is a common and serious acute neuropsychiatric syndrome characterized by inattention and global cognitive dysfunction." | 5.38 | Marked improvement in delirium with ramelteon: five case reports. ( Furuya, M; Horiguchi, J; Miyaoka, T; Otsuka, S; Tanaka, I; Wake, R; Yamashita, S; Yasuda, H, 2012) |
| " Forty-two participants developed delirium, but it was evenly distributed between the groups (melatonin 21/98, 21." | 5.34 | The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium. ( Almeida, OP; Anstey, M; Edwards, M; Flicker, L; Ford, AH; Kelly, R; Passage, J; Patel, H; Wibrow, B, 2020) |
| "The Basel BOMP-AID study is an investigator-initiated, single-centre, randomised controlled clinical trial for the treatment of hypoactive delirium with the once daily oral administration of melatonin 4 mg versus placebo in 190 critically ill patients." | 5.34 | Study protocol for a prospective randomised double-blind placebo-controlled clinical trial investigating a Better Outcome with Melatonin compared to Placebo Administered to normalize sleep-wake cycle and treat hypoactive ICU Delirium: the Basel BOMP-AID s ( Abdelhamid, S; Cajochen, C; Gebhard, CE; Hollinger, A; Huber, J; Reinhold, S; Siegemund, M; Steiner, LA; Sutter, R; Todorov, A; Tran, F; von Felten, S, 2020) |
| " The respective melatonin (n = 30) vs placebo (n = 30) outcomes were: incident delirium in 11/30 (36." | 5.34 | Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. ( Agar, M; Bush, SH; Currow, DC; Dasgupta, M; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Pereira, JL; Tierney, S, 2020) |
| "Postoperative delirium is a common problem associated with increased morbidity and mortality, prolonged hospital stay, additional tests and consultations and therefore, increased cost (1,2)." | 5.31 | Melatonin for treatment and prevention of postoperative delirium. ( Hanania, M; Kitain, E, 2002) |
| "In this randomized control trial, a total of 59 AOPP patients with subsequent delirium were randomly divided into two groups, the melatonin group (n=29) and the placebo-controlled group (n=30)." | 5.27 | Observation and analysis of clinical efficacy of melatonin on AOPP-induced delirium patients. ( Du, GH; Li, ZF; Pan, YY; Zhang, Y; Zhao, LB; Zhen, GD; Zhou, SZ, 2018) |
| "Studies suggest that melatonin may prevent delirium, a condition of acute brain dysfunction occurring in 20%-30% of hospitalized older adults that is associated with increased morbidity and mortality." | 5.27 | Melatonin and Sleep in Preventing Hospitalized Delirium: A Randomized Clinical Trial. ( Garcia, S; Jaiswal, SJ; Kang, DY; Loeks, M; Lu, CY; McCarthy, TJ; Owens, RL; Song, J; van Niekerk, CJ; Wineinger, NE, 2018) |
| "Although a previous review illustrated the efficacy of melatonin receptor agonists (MRAs) in preventing delirium, some recent randomized controlled trials (RCTs) did not confirm these effects." | 5.22 | Melatonin Receptor Agonists for the Prevention of Delirium: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Kawilapat, S; Kongsaengdao, S; Likhitsathian, S; Maneeton, B; Maneeton, N; Srisurapanont, M; Woottiluk, P, 2022) |
| "Studies on melatonin and melatonergic agents (MMA) for the prevention of postoperative delirium (POD) have produced inconsistent findings." | 5.22 | Melatonin and melatonergic agents for the prevention of postoperative delirium: A meta-analysis of randomized placebo-controlled trials. ( Wang, CM; Zhou, LY, 2022) |
| "The Healthy Heart-Mind trial is a randomized, double-blind, placebo-controlled clinical trial of 3 mg melatonin or matching placebo administered on seven consecutive days for the prevention of delirium following cardiac surgery." | 5.22 | The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial. ( Almeida, OP; Anstey, M; Edwards, M; Flicker, L; Ford, AH; Passage, J; Wibrow, B, 2016) |
| "Patients enrolled in a randomized controlled clinical trial of melatonin versus placebo on occurrence of delirium in hip-fracture patients." | 5.20 | In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration. ( Blom, MT; de Boer, A; de Jonghe, A; de Rooij, SE; Jansen, S; Tan, HL; van der Velde, N; van Munster, BC, 2015) |
| " Patients with or without delirium (as assessed using the Confusion Assessment Method for the ICU) were compared in terms of baseline characteristics and outcomes and the circadian rhythm of melatonin excretion using the 24-h excretion of its urinary metabolite 6-sulfatoxymelatonin (aMT6s)." | 5.20 | Delirium and Circadian Rhythm of Melatonin During Weaning From Mechanical Ventilation: An Ancillary Study of a Weaning Trial. ( Brochard, L; Brun-Buisson, C; Charles-Nelson, A; Dessap, AM; Katsahian, S; Launay, JM; Roche-Campo, F, 2015) |
| "To determine whether the postoperative administration of tryptophan would be beneficial for elderly adults undergoing surgery who are at risk of developing postoperative delirium." | 5.19 | Tryptophan supplementation and postoperative delirium--a randomized controlled trial. ( Adams, JC; Dunn, CL; Hawkins, CL; Moss, M; Raeburn, CD; Robinson, TN; Tran, ZV, 2014) |
| "In this older population with hip fracture, treatment with melatonin did not reduce the incidence of delirium." | 5.19 | Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. ( de Haan, RJ; de Jonghe, A; de Rooij, SE; Goslings, JC; Kloen, P; Levi, M; van Munster, BC; van Rees, C; van Velde, R; Wolvius, R, 2014) |
| ", melatonin) may have a role in the pathogenesis of delirium." | 5.15 | Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. ( Al-Aama, T; Brymer, C; Dasgupta, M; Esbaugh, J; Gutmanis, I; Woolmore-Goodwin, SM, 2011) |
| " In this review, we highlight these pathways as sources of serotonin and melatonin, which then regulate neurotransmission, influence circadian rhythm, cognitive functions, and the development of delirium." | 5.12 | Tryptophan: A Unique Role in the Critically Ill. ( Kanova, M; Kohout, P, 2021) |
| "Melatonin, a pineal gland hormone is reported to have a protective effect against delirium." | 5.12 | Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis. ( Khaing, K; Nair, BR, 2021) |
| " We reviewed the literature on the role of melatonin and ramelteon in the prevention of sleep disturbances and delirium in intensive care units and analysed the methods of melatonin therapy in an ICU setting." | 5.05 | The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit - a clinical review. ( Cubała, WJ; Lewandowska, K; Małkiewicz, MA; Mędrzycka-Dąbrowska, WA; Siemiński, M; Winklewski, PJ, 2020) |
| " Incidence of delirium was not significantly lower in patients who received melatonin, with an odd ratio, OR (95%Cl) of 0." | 5.05 | The effect of melatonin on delirium in hospitalised patients: A systematic review and meta-analyses with trial sequential analysis. ( Khor, AJ; Ng, KT; Teoh, WY, 2020) |
| " Studies reporting outcomes for melatonin or ramelteon use to prevent delirium in postoperative hospitalized patients (mean age ≥ 50 years) were eligible for inclusion." | 5.01 | Melatonin for the prevention of postoperative delirium in older adults: a systematic review and meta-analysis. ( Axon, DR; Campbell, AM; Lee, JK; Martin, JR; Mollon, L; Slack, MK, 2019) |
| "To investigate the efficacy of exogenous administration of melatonin and melatonin receptor agonists for the improvement of delirium, sleep, and other clinical outcomes of subjects in the intensive care unit (ICU)." | 5.01 | Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. ( Gao, F; Li, Z; Sun, W; Zhang, Q; Zhang, S, 2019) |
| "To review the prospective controlled trials available for the use of melatonin receptor agonists for delirium prevention." | 4.95 | Melatonin Receptor Agonists for Delirium Prevention. ( Gales, MA; Walker, CK, 2017) |
| "Recently, two high-quality clinical randomized controlled trials (RCTs) regarding the preventive effect of exogenous melatonin on delirium drew inconsistent conclusions." | 4.93 | Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials. ( Chen, S; Desislava, D; Liang, F; Shi, L; Wu, Q; Xu, L; Zhang, J, 2016) |
| "The objective of this review is to summarize the available data on the use of melatonin and melatonin agonist for the prevention and management of delirium in the elderly patients from randomized controlled trials (RCTs)." | 4.91 | Melatonin and melatonin agonist for delirium in the elderly patients. ( Chakraborti, D; Tampi, DJ; Tampi, RR, 2015) |
| ", risperidone or olanzapine), and melatonin may be effective in reducing the incidence of postoperative delirium, but the data are not robust." | 4.90 | Pharmacologic prevention of postoperative delirium. ( Gosch, M; Nicholas, JA, 2014) |
| " All papers on melatonin treatment in dementia were retrieved." | 4.86 | Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. ( de Jonghe, A; de Rooij, SE; Korevaar, JC; van Munster, BC, 2010) |
| "Melatonin has been trialed with reported increasing use for sleep dysregulation and prevention of ICU delirium in critically ill adults; however, reports of use in hospitalized pediatric patients are limited." | 4.02 | Melatonin Administration Patterns for Pediatric Inpatients in a Tertiary Children's Hospital. ( Kudchadkar, SR; Procaccini, DE, 2021) |
| "Consecutive patients admitted to the Tübingen University Stroke Unit, Tübingen, Germany, with acute ischemic stroke (AIS), who underwent standard care between August 2017 and December 2017, and patients who additionally received prophylactic melatonin (2 mg per day at night) within 24 h of symptom onset between August 2018 and December 2018 were included." | 4.02 | Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis. ( Boßelmann, C; Brendel, B; Fleischmann, R; Meisel, A; Mengel, A; Poli, S; Sartor-Pfeiffer, J; Stadler, V; Stefanou, MI; Ziemann, U; Zurloh, J, 2021) |
| "To compare the effect of prophylactic administration of melatonin, ramelteon, or no melatonin receptor agonist on the development of delirium in the intensive care unit (ICU)." | 4.02 | Evaluation of Delirium in Critically Ill Patients Prescribed Melatonin or Ramelteon. ( DeGrado, JR; Dube, KM; Lupi, KE; Romero, N, 2021) |
| "The development of ICU delirium was significantly lower in the melatonin group compared with that in the control group." | 3.91 | Effectiveness of Melatonin for the Prevention of Intensive Care Unit Delirium. ( Barnett, M; Baumgartner, L; Gross, K; Lai, J; Lam, K; Morris, A; Thompson, A, 2019) |
| " Exposure to melatonin or antipsychotic agents did not reduce the duration of ICU delirium, ICU/hospital length of stay, or 28-day mortality." | 3.88 | Pharmacologic Treatment of Intensive Care Unit Delirium and the Impact on Duration of Delirium, Length of Intensive Care Unit Stay, Length of Hospitalization, and 28-Day Mortality. ( Daniels, LM; Frank, RD; Nelson, SB; Park, JG, 2018) |
| "To assess if high morning plasma melatonin concentrations were associated with delirium." | 3.85 | Plasma melatonin levels in hip fracture patients with and without delirium: A confirmation study. ( de Rooij, SE; Kema, IP; Scholtens, RM; van Faassen, M; van Kempen, MF; van Munster, BC, 2017) |
| "Abnormalities in melatonin levels have been linked to delirium." | 3.85 | Role of Ramelteon in Reduction of As-Needed Antipsychotics in Elderly Patients with Delirium in a General Hospital Setting. ( Fazzari, M; James, SA; Lam, S; Pinkhasov, A; Singh, D, 2017) |
| "Preoperative CSF melatonin levels did not differ between patients with and without postoperative delirium." | 3.83 | Preoperative CSF Melatonin Concentrations and the Occurrence of Delirium in Older Hip Fracture Patients: A Preliminary Study. ( de Rooij, SE; Scholtens, RM; van Munster, BC; Vellekoop, AE; Vrouenraets, BC, 2016) |
| "To dynamic monitor and analyze the characteristic of polysomnography (PSG) and melatonin levels of delirium patients in intensive care unit (ICU)." | 3.80 | [Research of 24-hour dynamic sleep monitoring and melatonin changes in patients with delirium in intensive care unit]. ( Han, F; Liu, J; Sun, T; Sun, Y; Wang, X; Yang, J, 2014) |
| "We conducted a prospective observational study to assess the association of perioperative alteration of plasma melatonin concentration with delirium in 40 postoperative patients who required intensive care for more than 48 hours." | 3.79 | Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium. ( Egi, M; Kanazawa, T; Morimatsu, H; Morita, K; Toda, Y; Yoshitaka, S, 2013) |
| "All patients without delirium showed nearly identical preoperative and postoperative melatonin secretion for 24 hours, although peak values were significantly lower in patients more than 80 years old (7." | 3.71 | Postoperative delirium and melatonin levels in elderly patients. ( Ikeda, K; Kageyama, M; Machida, N; Menjo, M; Miura, M; Nimura, Y; Shigeta, H; Yasui, A, 2001) |
| "Delirium is highly prevalent in the intensive care unit (ICU) and is associated with adverse clinical outcomes." | 2.84 | Feasibility of melatonin for prevention of delirium in critically ill patients: a protocol for a multicentre, randomised, placebo-controlled study. ( Azad, A; Bernard, F; Burry, L; Detsky, M; Fan, E; Foster, J; Guenette, M; Mehta, S; Rose, L; Scales, D; Williamson, D, 2017) |
| "Melatonin is a naturally occurring, safe and cheap hormone that can be administered to improve sleep." | 2.84 | Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial. ( Anstey, M; Choo, L; Ford, A; Hardie, M; Hensley, M; Hillman, D; Kelty, E; Martinez, FE; Murray, K; Palmer, R; Roberts, B; Singh, B; Wibrow, B, 2017) |
| "Delirium is a common neuropsychiatric syndrome with considerable heterogeneity in clinical profile." | 2.82 | Psychometric evaluation of the DMSS-4 in a cohort of elderly post-operative hip fracture patients with delirium. ( Adamis, D; de Jonghe, A; de Rooij, SE; Meagher, DJ; Scholtens, RM; van Munster, BC, 2016) |
| "Delirium is a frequent, costly and morbid problem." | 2.82 | Moderate dose melatonin for the abatement and treatment of delirium in elderly general medical inpatients: study protocol of a placebo controlled, randomised, double blind trial. ( Clayton-Chubb, DI; Lange, PW, 2016) |
| "Melatonin plays an important role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism of melatonin might play an important role in the development of delirium." | 2.76 | The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial. ( de Jonghe, A; de Rooij, SE; Goslings, JC; Kloen, P; Korevaar, JC; Levi, MM; van Munster, BC; van Oosten, HE; van Rees, C; van Velde, R; Wolvius, R, 2011) |
| "Delirium is a very common but annoying clinical state that interferes with the treatment of background disease and delays recovery." | 2.72 | Elimination of the Causes of Poor Sleep Underlying Delirium is a Basic Strategy to Prevent Delirium. ( Enomoto, R; Lee-Hiraiwa, E, 2021) |
| "Postoperative delirium is a common sequela in older adults in the peri-operative period leading to poor outcomes with a complex pathophysiology which has led to a variety of different pharmacologic agents employed in attempts to prevent and treat this syndrome." | 2.66 | The pharmacotherapeutic management of postoperative delirium: an expert update. ( Scicutella, A, 2020) |
| "Delirium is a common mental disorder, which is distressing and has serious adverse outcomes in hospitalised patients." | 2.53 | Interventions for preventing delirium in hospitalised non-ICU patients. ( Clegg, A; Harrison, JK; Siddiqi, N; Simpkins, SA; Taylor, J; Teale, EA; Young, J, 2016) |
| "Melatonin levels have been shown to decline with aging." | 2.53 | Melatonin based therapies for delirium and dementia. ( Alagiakrishnan, K, 2016) |
| "Delirium is a common occurrence in older hospitalised patients, particularly in the setting of surgical intervention and acute illness." | 2.52 | Pharmacological interventions for preventing delirium in the elderly. ( Almeida, OP; Ford, AH, 2015) |
| "Delirium is a complex neurobehavioral syndrome caused by dysregulation of brain activity, characterized by an alteration in the level of attention and awareness, which develops over a short period of time and is seen as a change from the patient's baseline." | 2.50 | Delirium and its prevention with melatonergic drugs. ( Howland, RH, 2014) |
| "Delirium is a serious and common problem in severely medically ill patients of all ages." | 2.50 | The pharmacologic management of delirium in children and adolescents. ( Hanft, A; Turkel, SB, 2014) |
| "Delirium is a serious neuropsychiatric syndrome of acute onset that occurs in approximately one in five general hospital patients and is associated with serious adverse outcomes that include loss of adaptive function, persistent cognitive problems and increased mortality." | 2.49 | Delirium: a disturbance of circadian integrity? ( Adamis, D; Dunne, C; Fitzgerald, JM; Meagher, DJ; O'Regan, N; Timmons, S; Trzepacz, PT, 2013) |
| "Melatonin has a major role in control of circadian rhythm and sleep regulation and other effects on the immune system, neuroprotection, and oxidant/anti-oxidant activity." | 2.48 | Potential use of melatonin in sleep and delirium in the critically ill. ( Bellapart, J; Boots, R, 2012) |
| "Melatonin has been suggested as a low-risk pharmacological intervention to help prevent POD." | 1.72 | Melatonin for the prevention of postoperative delirium in older adults: a protocol for a systematic review and meta-analysis. ( Armstrong, RA; Barnes, J; Gibbison, B; Hinchliffe, R; Mouton, R; Pufulete, M; Sewart, E, 2022) |
| "Postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) are the most common central nervous system dysfunctions during the perioperative period." | 1.62 | Relationship among melatonin, postoperative delirium, and postoperative cognitive dysfunction. ( Mu, S; Wu, A; Wu, Y, 2021) |
| "Pediatric COVID-19 delirium is a new manifestation of the COVID-19 disease." | 1.62 | Pediatric COVID-19 Delirium: Case Report of 2 Adolescents. ( Bauer, SC; Logan, A; Manak, C; Mitchell, M; Moral, F; Preloger, E; Roman, M; Sandage, SJ; Spindler, A, 2021) |
| "Melatonin is an endogenous hormone exerting multiple biological effects, mainly in regulating diurnal rhythms, also in inflammatory process and immune response." | 1.56 | Assessment of melatonergics in prevention of delirium in critically ill patients: A protocol for systematic review and meta-analysis. ( Du, B; Huang, H; Jiang, Z; Li, W; Ren, C; Wang, Y; Xi, X; Yao, Y; Zhang, L; Zhu, Y, 2020) |
| "Both insomnia and its treatment can lead to the development of delirium in older adults." | 1.48 | Delirium associated with only one dose of zopiclone in an older adult. ( Isik, AT; Kalan, U; Soysal, P, 2018) |
| "Delirium is a syndrome characterized by acute fluctuations and alterations in attention and arousal." | 1.43 | Melatonin and melatonin agonists to prevent and treat delirium in critical illness: a systematic review protocol. ( Burry, LD; Cheung, A; Chimunda, T; Choong, K; Duffett, M; Foster, J; Guenette, M; Menon, K; Rose, L; Thabane, L, 2016) |
| "Delirium has been associated with morbidity and mortality including more ventilator days, longer ICU stay, increased long-term mortality and cognitive impairment." | 1.43 | Pharmacological interventions for delirium in intensive care patients: a protocol for an overview of reviews. ( Barbateskovic, M; Jakobsen, JC; Larsen, LK; Oxenbøll-Collet, M; Perner, A; Wetterslev, J, 2016) |
| "Delirium is an acute-onset syndrome that exacerbates patients' condition and significantly increases consequential morbidity and mortality." | 1.42 | The diurnal profile of melatonin during delirium in elderly patients--preliminary results. ( Grodzicki, T; Klich-Rączka, A; Pac, A; Piotrowicz, K; Zdzienicka, A, 2015) |
| "Melatonin has a key role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism of melatonin might play an important role in the development of delirium." | 1.38 | [Delirium, insomnia in hospitalization and ramelteon]. ( Ito, T, 2012) |
| "Delirium is a common and serious acute neuropsychiatric syndrome characterized by inattention and global cognitive dysfunction." | 1.38 | Marked improvement in delirium with ramelteon: five case reports. ( Furuya, M; Horiguchi, J; Miyaoka, T; Otsuka, S; Tanaka, I; Wake, R; Yamashita, S; Yasuda, H, 2012) |
| "Delirium is a common syndrome among hospitalized elderly patients." | 1.32 | The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. ( Balan, S; Blagman, B; Chana, W; Habot, B; Leibovitz, A; Neumann, E; Rahel, B; Richard, G; Ruth, M; Yassica, B; Zila, SO, 2003) |
| "Postoperative delirium is a common problem associated with increased morbidity and mortality, prolonged hospital stay, additional tests and consultations and therefore, increased cost (1,2)." | 1.31 | Melatonin for treatment and prevention of postoperative delirium. ( Hanania, M; Kitain, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.03) | 18.2507 |
| 2000's | 9 (9.28) | 29.6817 |
| 2010's | 50 (51.55) | 24.3611 |
| 2020's | 37 (38.14) | 2.80 |
| Authors | Studies |
|---|---|
| Mu, S | 1 |
| Wu, Y | 1 |
| Wu, A | 1 |
| Procaccini, DE | 1 |
| Kudchadkar, SR | 1 |
| Shi, Y | 1 |
| Kanova, M | 1 |
| Kohout, P | 1 |
| Sigaut, S | 1 |
| Couffignal, C | 1 |
| Esposito-Farèse, M | 1 |
| Degos, V | 1 |
| Molliex, S | 1 |
| Boddaert, J | 1 |
| Raynaud-Simon, A | 1 |
| Durand-Zaleski, I | 1 |
| Marcault, E | 1 |
| Jacota, M | 1 |
| Dahmani, S | 1 |
| Paugam-Burtz, C | 1 |
| Weiss, E | 1 |
| Wibrow, B | 5 |
| Martinez, FE | 3 |
| Myers, E | 2 |
| Chapman, A | 1 |
| Litton, E | 2 |
| Ho, KM | 2 |
| Regli, A | 1 |
| Hawkins, D | 1 |
| Ford, A | 3 |
| van Haren, FMP | 1 |
| Wyer, S | 1 |
| McCaffrey, J | 1 |
| Rashid, A | 1 |
| Kelty, E | 3 |
| Murray, K | 3 |
| Anstey, M | 5 |
| Yin, B | 1 |
| Ye, T | 1 |
| Liu, X | 1 |
| Wan, R | 1 |
| Gu, L | 1 |
| Zong, G | 1 |
| Burry, L | 2 |
| Sonneville, R | 1 |
| Ely, EW | 1 |
| Maneeton, B | 1 |
| Kongsaengdao, S | 1 |
| Maneeton, N | 1 |
| Likhitsathian, S | 1 |
| Woottiluk, P | 1 |
| Kawilapat, S | 1 |
| Srisurapanont, M | 1 |
| Lee, EY | 1 |
| Wilcox, ME | 1 |
| Sewart, E | 1 |
| Barnes, J | 1 |
| Armstrong, RA | 1 |
| Pufulete, M | 1 |
| Hinchliffe, R | 1 |
| Gibbison, B | 1 |
| Mouton, R | 1 |
| Yu, CL | 1 |
| Carvalho, AF | 1 |
| Thompson, T | 1 |
| Tsai, TC | 1 |
| Tseng, PT | 2 |
| Tu, YK | 1 |
| Yang, SN | 1 |
| Yang, FC | 1 |
| Chang, CH | 1 |
| Hsu, CW | 1 |
| Hsu, TW | 1 |
| Liang, CS | 1 |
| Beaucage-Charron, J | 1 |
| Rinfret, J | 1 |
| Coveney, R | 1 |
| Williamson, D | 2 |
| Duan, Y | 1 |
| Yang, Y | 1 |
| Zhu, W | 1 |
| Wan, L | 1 |
| Wang, G | 2 |
| Yue, J | 1 |
| Bao, Q | 1 |
| Shao, J | 1 |
| Wan, X | 1 |
| Moeri, L | 1 |
| Mini, P | 1 |
| Gironi, C | 1 |
| Eshmawey, M | 1 |
| Ford, AH | 3 |
| Flicker, L | 2 |
| Kelly, R | 1 |
| Patel, H | 1 |
| Passage, J | 2 |
| Edwards, M | 2 |
| Almeida, OP | 3 |
| Campbell, AM | 1 |
| Axon, DR | 1 |
| Martin, JR | 1 |
| Slack, MK | 1 |
| Mollon, L | 1 |
| Lee, JK | 1 |
| Yang, CP | 1 |
| Pei-Chen Chang, J | 1 |
| Su, H | 1 |
| Satyanarayanan, SK | 1 |
| Su, KP | 1 |
| Zhu, Y | 1 |
| Jiang, Z | 1 |
| Huang, H | 1 |
| Wang, Y | 1 |
| Zhang, L | 1 |
| Ren, C | 1 |
| Yao, Y | 1 |
| Li, W | 1 |
| Du, B | 1 |
| Xi, X | 1 |
| Lange, PW | 2 |
| Clayton-Chubb, DI | 2 |
| Watson, R | 1 |
| Maier, AB | 1 |
| Lewandowska, K | 1 |
| Małkiewicz, MA | 1 |
| Siemiński, M | 1 |
| Cubała, WJ | 1 |
| Winklewski, PJ | 1 |
| Mędrzycka-Dąbrowska, WA | 1 |
| Scicutella, A | 1 |
| Shen, QH | 1 |
| Li, HF | 1 |
| Zhou, XY | 1 |
| Lu, YP | 1 |
| Yuan, XZ | 1 |
| Enomoto, R | 1 |
| Lee-Hiraiwa, E | 1 |
| Hollinger, A | 1 |
| von Felten, S | 1 |
| Sutter, R | 1 |
| Huber, J | 1 |
| Tran, F | 1 |
| Reinhold, S | 1 |
| Abdelhamid, S | 1 |
| Todorov, A | 1 |
| Gebhard, CE | 1 |
| Cajochen, C | 1 |
| Steiner, LA | 1 |
| Siegemund, M | 1 |
| Zambrelli, E | 2 |
| Canevini, M | 1 |
| Gambini, O | 1 |
| D'Agostino, A | 2 |
| Wiwanitkit, V | 1 |
| Lawlor, PG | 1 |
| McNamara-Kilian, MT | 1 |
| MacDonald, AR | 1 |
| Momoli, F | 1 |
| Tierney, S | 1 |
| Lacaze-Masmonteil, N | 1 |
| Dasgupta, M | 2 |
| Agar, M | 1 |
| Pereira, JL | 1 |
| Currow, DC | 1 |
| Bush, SH | 1 |
| Khaing, K | 1 |
| Nair, BR | 1 |
| Yuan, Y | 1 |
| Song, Y | 1 |
| Jia, Y | 1 |
| Zhou, Y | 1 |
| Mi, X | 1 |
| Jia, X | 1 |
| Wang, X | 2 |
| Liu, C | 1 |
| Li, Y | 1 |
| Shi, C | 1 |
| Han, Y | 1 |
| Guo, X | 1 |
| Zhang, W | 1 |
| Li, Z | 2 |
| Mengel, A | 1 |
| Zurloh, J | 1 |
| Boßelmann, C | 1 |
| Brendel, B | 1 |
| Stadler, V | 1 |
| Sartor-Pfeiffer, J | 1 |
| Meisel, A | 1 |
| Fleischmann, R | 1 |
| Ziemann, U | 1 |
| Poli, S | 1 |
| Stefanou, MI | 1 |
| Romero, N | 1 |
| Dube, KM | 1 |
| Lupi, KE | 1 |
| DeGrado, JR | 1 |
| Javaherforoosh Zadeh, F | 1 |
| Janatmakan, F | 1 |
| Shafaeebejestan, E | 1 |
| Jorairahmadi, S | 1 |
| Wang, CM | 1 |
| Zhou, LY | 1 |
| Bauer, SC | 1 |
| Moral, F | 1 |
| Preloger, E | 1 |
| Spindler, A | 1 |
| Roman, M | 1 |
| Logan, A | 1 |
| Sandage, SJ | 1 |
| Manak, C | 1 |
| Mitchell, M | 1 |
| Scales, D | 1 |
| Foster, J | 2 |
| Mehta, S | 1 |
| Guenette, M | 2 |
| Fan, E | 1 |
| Detsky, M | 1 |
| Azad, A | 1 |
| Bernard, F | 1 |
| Rose, L | 2 |
| Scholtens, RM | 3 |
| van Munster, BC | 10 |
| van Faassen, M | 1 |
| van Kempen, MF | 1 |
| Kema, IP | 1 |
| de Rooij, SE | 10 |
| Pinkhasov, A | 1 |
| James, SA | 1 |
| Fazzari, M | 1 |
| Singh, D | 1 |
| Lam, S | 1 |
| Zhao, LB | 1 |
| Zhen, GD | 1 |
| Zhang, Y | 1 |
| Pan, YY | 1 |
| Du, GH | 1 |
| Zhou, SZ | 1 |
| Li, ZF | 1 |
| Jaiswal, SJ | 1 |
| McCarthy, TJ | 1 |
| Wineinger, NE | 1 |
| Kang, DY | 1 |
| Song, J | 1 |
| Garcia, S | 1 |
| van Niekerk, CJ | 1 |
| Lu, CY | 1 |
| Loeks, M | 1 |
| Owens, RL | 1 |
| Kalan, U | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| Daniels, LM | 1 |
| Nelson, SB | 1 |
| Frank, RD | 1 |
| Park, JG | 1 |
| Baumgartner, L | 1 |
| Lam, K | 1 |
| Lai, J | 1 |
| Barnett, M | 1 |
| Thompson, A | 1 |
| Gross, K | 1 |
| Morris, A | 1 |
| Marra, A | 1 |
| McGrane, TJ | 1 |
| Henson, CP | 1 |
| Pandharipande, PP | 1 |
| Zhang, Q | 1 |
| Gao, F | 1 |
| Zhang, S | 1 |
| Sun, W | 1 |
| Ng, KT | 1 |
| Teoh, WY | 1 |
| Khor, AJ | 1 |
| Liu, D | 1 |
| An, YZ | 1 |
| Lammers, M | 1 |
| Ahmed, AIA | 1 |
| Fitzgerald, JM | 1 |
| Adamis, D | 2 |
| Trzepacz, PT | 1 |
| O'Regan, N | 1 |
| Timmons, S | 1 |
| Dunne, C | 1 |
| Meagher, DJ | 2 |
| van de Glind, EM | 1 |
| Vural, EM | 1 |
| Scholten, E | 1 |
| Hooft, L | 1 |
| Portegijs, E | 1 |
| de Jonghe, A | 6 |
| Gosch, M | 1 |
| Nicholas, JA | 1 |
| Howland, RH | 1 |
| Turkel, SB | 1 |
| Hanft, A | 1 |
| Chakraborti, D | 1 |
| Tampi, DJ | 1 |
| Tampi, RR | 1 |
| Robinson, TN | 1 |
| Dunn, CL | 1 |
| Adams, JC | 1 |
| Hawkins, CL | 1 |
| Tran, ZV | 1 |
| Raeburn, CD | 1 |
| Moss, M | 1 |
| Goslings, JC | 2 |
| Kloen, P | 2 |
| van Rees, C | 2 |
| Wolvius, R | 2 |
| van Velde, R | 2 |
| Levi, M | 1 |
| de Haan, RJ | 1 |
| Sun, T | 1 |
| Han, F | 1 |
| Sun, Y | 1 |
| Liu, J | 1 |
| Yang, J | 1 |
| Blom, MT | 1 |
| Jansen, S | 1 |
| de Boer, A | 1 |
| Tan, HL | 1 |
| van der Velde, N | 1 |
| Mo, Y | 1 |
| Scheer, CE | 1 |
| Abdallah, GT | 1 |
| Madrid-Navarro, CJ | 1 |
| Sanchez-Galvez, R | 1 |
| Martinez-Nicolas, A | 1 |
| Marina, R | 1 |
| Garcia, JA | 1 |
| Madrid, JA | 1 |
| Rol, MA | 1 |
| Dessap, AM | 1 |
| Roche-Campo, F | 1 |
| Launay, JM | 1 |
| Charles-Nelson, A | 1 |
| Katsahian, S | 1 |
| Brun-Buisson, C | 1 |
| Brochard, L | 2 |
| Chen, S | 1 |
| Shi, L | 1 |
| Liang, F | 1 |
| Xu, L | 1 |
| Desislava, D | 1 |
| Wu, Q | 1 |
| Zhang, J | 1 |
| Piotrowicz, K | 1 |
| Klich-Rączka, A | 1 |
| Pac, A | 1 |
| Zdzienicka, A | 1 |
| Grodzicki, T | 1 |
| Siddiqi, N | 1 |
| Harrison, JK | 1 |
| Clegg, A | 1 |
| Teale, EA | 1 |
| Young, J | 1 |
| Taylor, J | 1 |
| Simpkins, SA | 1 |
| Alagiakrishnan, K | 1 |
| Messerschmidt, K | 1 |
| Walker, CK | 1 |
| Gales, MA | 1 |
| Burry, LD | 1 |
| Thabane, L | 1 |
| Choong, K | 1 |
| Menon, K | 1 |
| Duffett, M | 1 |
| Cheung, A | 1 |
| Chimunda, T | 1 |
| Barbateskovic, M | 1 |
| Larsen, LK | 1 |
| Oxenbøll-Collet, M | 1 |
| Jakobsen, JC | 1 |
| Perner, A | 1 |
| Wetterslev, J | 1 |
| Vellekoop, AE | 1 |
| Vrouenraets, BC | 1 |
| Roberts, B | 1 |
| Hardie, M | 1 |
| Palmer, R | 1 |
| Choo, L | 1 |
| Hillman, D | 1 |
| Hensley, M | 1 |
| Singh, B | 1 |
| Yousaf, F | 1 |
| Seet, E | 1 |
| Venkatraghavan, L | 1 |
| Katznelson, R | 1 |
| Chung, F | 1 |
| Al-Aama, T | 1 |
| Brymer, C | 1 |
| Gutmanis, I | 1 |
| Woolmore-Goodwin, SM | 1 |
| Esbaugh, J | 1 |
| Korevaar, JC | 2 |
| van Oosten, HE | 1 |
| Levi, MM | 1 |
| Bellapart, J | 1 |
| Boots, R | 1 |
| Ito, T | 1 |
| Furuya, M | 1 |
| Miyaoka, T | 1 |
| Yasuda, H | 1 |
| Yamashita, S | 1 |
| Tanaka, I | 1 |
| Otsuka, S | 1 |
| Wake, R | 1 |
| Horiguchi, J | 1 |
| Yoshitaka, S | 1 |
| Egi, M | 1 |
| Morimatsu, H | 1 |
| Kanazawa, T | 1 |
| Toda, Y | 1 |
| Morita, K | 1 |
| Balan, S | 1 |
| Leibovitz, A | 1 |
| Zila, SO | 1 |
| Ruth, M | 1 |
| Chana, W | 1 |
| Yassica, B | 1 |
| Rahel, B | 1 |
| Richard, G | 1 |
| Neumann, E | 1 |
| Blagman, B | 1 |
| Habot, B | 1 |
| Lewis, MC | 1 |
| Barnett, SR | 1 |
| Marcantonio, ER | 1 |
| Rudolph, JL | 1 |
| Culley, D | 1 |
| Crosby, G | 1 |
| Alsop, D | 1 |
| Inouye, SK | 1 |
| Short, MR | 1 |
| Winstead, PS | 1 |
| Sharer, J | 1 |
| Drouot, X | 1 |
| Cabello, B | 1 |
| d'Ortho, MP | 1 |
| Uchida, K | 1 |
| Aoki, T | 1 |
| Ishizuka, B | 1 |
| Sher, L | 1 |
| Shigeta, H | 1 |
| Yasui, A | 1 |
| Nimura, Y | 1 |
| Machida, N | 1 |
| Kageyama, M | 1 |
| Miura, M | 1 |
| Menjo, M | 1 |
| Ikeda, K | 1 |
| Hanania, M | 1 |
| Kitain, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients: a Randomized Controlled Trial[NCT04335968] | Phase 3 | 790 participants (Anticipated) | Interventional | 2021-01-23 | Recruiting | ||
| Better Outcome With Melatonin Compared to Placebo Administered to Normalize Sleep-wake Cycle and Treat Hypoactive ICU Delirium The Basel BOMP-AID Randomized Trial[NCT03438526] | Phase 4 | 190 participants (Anticipated) | Interventional | 2022-01-03 | Recruiting | ||
| The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172] | Phase 2 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| DELIRE-ICU: A Randomised Controlled Feasibility Trial of Melatonin vs Placebo in the Treatment of Delirium in the Intensive Care Unit[NCT05713877] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | ||
| Feasibility of Melatonin for Prevention of Delirium in Critically Ill Patients: a Multi-centre, Randomized, Placebo-controlled Study.[NCT02615340] | Phase 2 | 69 participants (Anticipated) | Interventional | 2017-10-12 | Recruiting | ||
| Melatonin and Sleep in Preventing Delirium in the Hospital: A Randomized Placebo-controlled Trial[NCT02597231] | Phase 1/Phase 2 | 94 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Use of Melatonin for Prevention of POCD After TURP Surgery Under Spinal Anesthesia for Elderly Patients[NCT03966950] | 104 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | |||
| Melatonin Use in the Intensive Care Elderly Population[NCT03013790] | Phase 4 | 600 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Prevention of Delirium in Inpatients Utilizing Melatonin[NCT02654314] | Phase 3 | 277 participants (Actual) | Interventional | 2016-07-31 | Terminated (stopped due to Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.) | ||
| Impact of Low-dose Dexmedetomidine on Outcomes of Elderly Admitted to ICU After Noncardiac Surgery: a Randomized Controlled Trial[NCT04204798] | 1,410 participants (Anticipated) | Interventional | 2020-08-28 | Recruiting | |||
| Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study[NCT05307003] | 60 participants (Anticipated) | Observational | 2023-04-01 | Recruiting | |||
| Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study)[NCT05085808] | Phase 4 | 30 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B[NCT00473148] | Phase 3 | 265 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Impact of Dexmedetomidine Supplemented Analgesia on Long-term Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial[NCT03012971] | 1,500 participants (Actual) | Interventional | 2017-01-06 | Active, not recruiting | |||
| Evaluating the Effects of Implementing an Scenario-based Education Initiative and OSCE for Recognition and Management of Delirium in Adult Intensive Care Unit: Randomised Controlled Trial[NCT03642249] | 72 participants (Actual) | Interventional | 2019-11-05 | Completed | |||
| Impact of Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block on Postoperative Delirium and Long-term Oucomes in Elderly Patients After Single Knee Arthroplasty[NCT03629483] | Phase 4 | 736 participants (Anticipated) | Interventional | 2018-12-10 | Suspended (stopped due to Trial stopped by the sponsor because of no funding.) | ||
| Can the Hospital's Architectural Design Affect the Incidence and Treatment of Delirium in Geriatric Patients? A Comparison Between Single-bed and Multibed Rooms[NCT03199768] | 1,014 participants (Actual) | Observational | 2016-09-15 | Completed | |||
| Predict IQCODE Delirium in Geriatric Patients[NCT03175276] | 315 participants (Actual) | Observational | 2017-03-20 | Completed | |||
| Impact of Dexmedetomidine Supplemented Intravenous Analgesia on Postoperative Delirium and Long-term Outcomes in Elderly After Orthopedic Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial[NCT03629262] | Phase 4 | 712 participants (Actual) | Interventional | 2018-10-28 | Active, not recruiting | ||
| Impact of Dexmedetomidine Supplemented Analgesia on Incidence of Delirium in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial[NCT03012984] | 1,500 participants (Actual) | Interventional | 2017-01-06 | Completed | |||
| Validation of Cerebral Non-invasive Monitoring and Prediction of Post-operative Delirium and Outcomes: A Prospective Observational Study[NCT04643834] | 151 participants (Anticipated) | Observational | 2019-11-21 | Recruiting | |||
| Impact of Perioperative Nutritional Intervention on Perioperative Outcomes of Elderly Patients Having Hip Fracture Surgery: A Randomized Control Trial[NCT04451538] | 970 participants (Anticipated) | Interventional | 2020-12-28 | Recruiting | |||
| The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery[NCT02691013] | 120 participants (Actual) | Interventional | 2016-02-29 | Active, not recruiting | |||
| Effects of Perioperative Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery[NCT01505465] | 50 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Association of Plasma Melatonin Levels With Delirium After Sevoflurane Anesthesia[NCT01570881] | 33 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Relationship Between Asynchronies and Sleep Disruption in Mechanically Ventilated Patients: a Prospective Cohort Study[NCT05847374] | 50 participants (Actual) | Observational | 2019-01-01 | Completed | |||
| Effect of Sleep Disruption on the Outcome of Weaning From Mechanical Ventilation[NCT02464735] | 44 participants (Actual) | Observational | 2016-01-01 | Completed | |||
| Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | days (Median) |
|---|---|
| Melatonin | 0 |
| Cellulose Microcrystylline | 0 |
Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 2 |
| Cellulose Microcrystylline | 8 |
Length of stay is defined as the total time hospitalized for the acute illness (in days). (NCT02654314)
Timeframe: from day of admission to completion of acute care, not to exceed 30 days
| Intervention | days (Mean) |
|---|---|
| Melatonin | 4.58 |
| Cellulose Microcrystylline | 4.71 |
Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | number of doses per days of hospitalizat (Median) |
|---|---|
| Melatonin | 0 |
| Cellulose Microcrystylline | 0 |
Measured twice daily during the ICU stay using the Confusions Assessment Method instrument. (NCT02691013)
Timeframe: Twice daily for up to 10 days
| Intervention | hours (Median) |
|---|---|
| Placebo | 16 |
| Ramelteon | 24 |
(NCT02691013)
Timeframe: Duration of hospital admission
| Intervention | days (Median) |
|---|---|
| Placebo | 12 |
| Ramelteon | 12 |
(NCT02691013)
Timeframe: Duration of hospital admission
| Intervention | days (Median) |
|---|---|
| Placebo | 4 |
| Ramelteon | 4 |
Measured twice daily over the course of the ICU stay using the Confusion Assessment Method instrument (NCT02691013)
Timeframe: Twice daily for up to 10 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 22 |
| Ramelteon | 19 |
Sleep time change from 96 hours before surgery to 72 hours after surgery (NCT01505465)
Timeframe: 96 hours before surgery to 72 hours after surgery
| Intervention | minutes (Mean) |
|---|---|
| Study: Melatonin | 20 |
| Control: Placebo | -55 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | volume percentage (vol%) of red blood ce (Median) |
|---|---|
| Bright Light Therapy | 28.20 |
| Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | g/dl (Median) |
|---|---|
| Bright Light Therapy | 9.70 |
| Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | days (Median) |
|---|---|
| Bright Light Therapy | 18 |
| Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Bright Light Therapy | 1 |
| Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | thousand cells/uL (Median) |
|---|---|
| Bright Light Therapy | 39 |
| Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | M/uL (Median) |
|---|---|
| Bright Light Therapy | 3.21 |
| Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
| Intervention | units on a scale (Number) |
|---|---|
| Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | K/uL (Median) |
|---|---|
| Bright Light Therapy | 2.30 |
| Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mg/dl (Median) | |
|---|---|---|
| Serum Creatinine | Blood Urea Nitrogen (BUN) | |
| Bright Light Therapy | 0.66 | 9 |
| Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mmol/L (Median) | |||
|---|---|---|---|---|
| Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
| Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
| Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
37 reviews available for melatonin and Delirium
| Article | Year |
|---|---|
Tryptophan: A Unique Role in the Critically Ill.
Topics: Critical Illness; Delirium; Depression; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; | 2021 |
Melatonin Receptor Agonists for the Prevention of Delirium: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Delirium; Humans; Indenes; Melatonin; Randomized Controlled Trials as Topic; Receptors, Melato | 2022 |
Sleep in the intensive care unit.
Topics: Critical Care; Delirium; Dexmedetomidine; Humans; Intensive Care Units; Melatonin; Sleep | 2022 |
Ramelteon for delirium prevention in hospitalized patients: An updated meta-analysis and trial sequential analysis of randomized controlled trials.
Topics: Delirium; Humans; Melatonin; Middle Aged; Randomized Controlled Trials as Topic; Reproducibility of | 2023 |
Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis.
Topics: Aged; Antipsychotic Agents; Delirium; Humans; Indenes; Melatonin | 2023 |
Melatonin intervention to prevent delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials.
Topics: Delirium; Humans; Intensive Care Units; Length of Stay; Melatonin; Randomized Controlled Trials as T | 2023 |
Melatonin for the prevention of postoperative delirium in older adults: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Humans; Incidence; Melatonin; | 2019 |
Melatonergic agents in the prevention of delirium: A network meta-analysis of randomized controlled trials.
Topics: Aged; Delirium; Humans; Indenes; Melatonin; Network Meta-Analysis; Randomized Controlled Trials as T | 2020 |
The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit - a clinical review.
Topics: Chronobiology Disorders; Delirium; Humans; Indenes; Intensive Care Units; Melatonin; Receptors, Mela | 2020 |
The pharmacotherapeutic management of postoperative delirium: an expert update.
Topics: Aged; Analgesia; Anesthesia; Antipsychotic Agents; Delirium; Dexmedetomidine; Drug Monitoring; Human | 2020 |
Elimination of the Causes of Poor Sleep Underlying Delirium is a Basic Strategy to Prevent Delirium.
Topics: Adenosine; Animals; Cholinergic Antagonists; Delirium; Histamine; Humans; Melatonin; Sleep; Sleep Qu | 2021 |
Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis.
Topics: Adult; Delirium; Humans; Hypnotics and Sedatives; Intensive Care Units; Length of Stay; Melatonin | 2021 |
Melatonin and melatonergic agents for the prevention of postoperative delirium: A meta-analysis of randomized placebo-controlled trials.
Topics: Adult; Aged; Anesthesia, General; Delirium; Humans; Incidence; Melatonin; Randomized Controlled Tria | 2022 |
Melatonin in Critical Care.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Critical Care; | 2019 |
Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Benzofurans; Case-Control Studies; Correlation of Data; Cross-Sectional Studies; Cyclopropane | 2019 |
The effect of melatonin on delirium in hospitalised patients: A systematic review and meta-analyses with trial sequential analysis.
Topics: Delirium; Dizziness; Headache; Hospital Mortality; Humans; Hypnotics and Sedatives; Incidence; Inden | 2020 |
Melatonin deficiency hypothesis in delirium: a synthesis of current evidence.
Topics: Animals; Circadian Rhythm; Delirium; Humans; Melatonin; Models, Biological; Risk Factors | 2013 |
[Melatonin and delirium].
Topics: Delirium; Humans; Melatonin | 2013 |
Delirium: a disturbance of circadian integrity?
Topics: Ataxia; Chronobiology Disorders; Cognition Disorders; Delirium; Humans; Melatonin; Models, Biologica | 2013 |
Pharmacologic prevention of postoperative delirium.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Evidence-Based Medicine; Female; Humans; Hy | 2014 |
Delirium and its prevention with melatonergic drugs.
Topics: Delirium; Humans; Melatonin | 2014 |
The pharmacologic management of delirium in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Delirium; Dexmedetomidine; Dibenzothiazepi | 2014 |
Melatonin and melatonin agonist for delirium in the elderly patients.
Topics: Aged; Delirium; Humans; Indenes; Melatonin; Randomized Controlled Trials as Topic | 2015 |
Pharmacological interventions for preventing delirium in the elderly.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Antipsychotic Agents; Delirium; Dexmedetomidine; Hospita | 2015 |
Emerging Role of Melatonin and Melatonin Receptor Agonists in Sleep and Delirium in Intensive Care Unit Patients.
Topics: Central Nervous System Depressants; Critical Care; Critical Illness; Delirium; Humans; Indenes; Inte | 2016 |
Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment.
Topics: Animals; Chronobiology Disorders; Circadian Rhythm; Critical Illness; Delirium; Humans; Intensive Ca | 2015 |
Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment.
Topics: Animals; Chronobiology Disorders; Circadian Rhythm; Critical Illness; Delirium; Humans; Intensive Ca | 2015 |
Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment.
Topics: Animals; Chronobiology Disorders; Circadian Rhythm; Critical Illness; Delirium; Humans; Intensive Ca | 2015 |
Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment.
Topics: Animals; Chronobiology Disorders; Circadian Rhythm; Critical Illness; Delirium; Humans; Intensive Ca | 2015 |
Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials.
Topics: Aged; Aged, 80 and over; Delirium; Female; Humans; Indenes; Male; Melatonin; Outcome Assessment, Hea | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Interventions for preventing delirium in hospitalised non-ICU patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Antipsychotic Agents; Cholinesterase Inhibitors; Cyti | 2016 |
Melatonin based therapies for delirium and dementia.
Topics: Aged; Animals; Antipsychotic Agents; Benzodiazepines; Chronobiology Phenomena; Clinical Trials as To | 2016 |
Melatonin Receptor Agonists for Delirium Prevention.
Topics: Clinical Trials as Topic; Delirium; Female; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Pro | 2017 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Potential use of melatonin in sleep and delirium in the critically ill.
Topics: Central Nervous System Depressants; Critical Care; Critical Illness; Delirium; Humans; Intensive Car | 2012 |
Potential use of melatonin in sleep and delirium in the critically ill.
Topics: Central Nervous System Depressants; Critical Care; Critical Illness; Delirium; Humans; Intensive Car | 2012 |
Potential use of melatonin in sleep and delirium in the critically ill.
Topics: Central Nervous System Depressants; Critical Care; Critical Illness; Delirium; Humans; Intensive Car | 2012 |
Potential use of melatonin in sleep and delirium in the critically ill.
Topics: Central Nervous System Depressants; Critical Care; Critical Illness; Delirium; Humans; Intensive Car | 2012 |
Serum biomarkers for delirium.
Topics: Acetylcholine; Amino Acids; Biomarkers; Cholinergic Antagonists; Delirium; Genetic Markers; Humans; | 2006 |
Delirium dilemma.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; | 2007 |
Tackling sundowning in a patient with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Circadian Rhyt | 2008 |
Sleep in the intensive care unit.
Topics: Circadian Rhythm; Delirium; Humans; Hypnotics and Sedatives; Immunocompetence; Injury Severity Score | 2008 |
Sleep in the intensive care unit.
Topics: Circadian Rhythm; Delirium; Humans; Hypnotics and Sedatives; Immunocompetence; Injury Severity Score | 2008 |
Sleep in the intensive care unit.
Topics: Circadian Rhythm; Delirium; Humans; Hypnotics and Sedatives; Immunocompetence; Injury Severity Score | 2008 |
Sleep in the intensive care unit.
Topics: Circadian Rhythm; Delirium; Humans; Hypnotics and Sedatives; Immunocompetence; Injury Severity Score | 2008 |
Postoperative delirium and plasma melatonin.
Topics: Delirium; Humans; Interferons; Melatonin; Models, Biological; Postoperative Complications; Renal Dia | 1999 |
24 trials available for melatonin and Delirium
| Article | Year |
|---|---|
Effects of Melatonin on Postoperative Delirium After PCI in Elderly Patients: A Randomized, Single-Center, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Coronary Care Units; Delirium; Double-Blind Method; Female; Humans; Incidence; Intention to Tr | 2021 |
Melatonin for prevention of postoperative delirium after lower limb fracture surgery in elderly patients (DELIRLESS): study protocol for a multicentre randomised controlled trial.
Topics: Aged; Delirium; Double-Blind Method; Hip Fractures; Humans; Lower Extremity; Melatonin; Multicenter | 2021 |
Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial.
Topics: Australia; Critical Care; Critical Illness; Delirium; Double-Blind Method; Humans; Intensive Care Un | 2022 |
Effects of Melatonin for Delirium in Elderly Acute Heart Failure Patients: A Randomized, Single-Center, Double-Blind, and Placebo-Controlled Trial.
Topics: Aged; Delirium; Double-Blind Method; Heart Failure; Humans; Length of Stay; Melatonin; Treatment Out | 2022 |
The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium.
Topics: Aged; Cardiac Surgical Procedures; Coronary Artery Bypass; Delirium; Double-Blind Method; Female; Hu | 2020 |
Results from a double blinded, randomised, placebo-controlled, feasibility trial of melatonin for the treatment of delirium in older medical inpatients.
Topics: Aged; Delirium; Double-Blind Method; Feasibility Studies; Humans; Inpatients; Melatonin | 2021 |
Study protocol for a prospective randomised double-blind placebo-controlled clinical trial investigating a Better Outcome with Melatonin compared to Placebo Administered to normalize sleep-wake cycle and treat hypoactive ICU Delirium: the Basel BOMP-AID s
Topics: Activities of Daily Living; Delirium; Double-Blind Method; Humans; Intensive Care Units; Melatonin; | 2020 |
Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial.
Topics: Aged; Delirium; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Melatonin; Middle Ag | 2020 |
Statistical analysis plan for the Prophylactic Melatonin for Delirium in Intensive Care (ProMEDIC): a randomised controlled trial.
Topics: Australia; Critical Care; Delirium; Double-Blind Method; Humans; Intensive Care Units; Melatonin; Tr | 2021 |
Effect of Melatonin on Delirium After on-Pump Coronary Artery Bypass Graft Surgery: A Randomized Clinical Trial.
Topics: Aged; Coronary Artery Bypass; Delirium; Double-Blind Method; Female; Humans; Iran; Male; Melatonin; | 2021 |
Feasibility of melatonin for prevention of delirium in critically ill patients: a protocol for a multicentre, randomised, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Central Nervous System Depressants; Critical Illness; Delirium; Female; Hum | 2017 |
Feasibility of melatonin for prevention of delirium in critically ill patients: a protocol for a multicentre, randomised, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Central Nervous System Depressants; Critical Illness; Delirium; Female; Hum | 2017 |
Feasibility of melatonin for prevention of delirium in critically ill patients: a protocol for a multicentre, randomised, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Central Nervous System Depressants; Critical Illness; Delirium; Female; Hum | 2017 |
Feasibility of melatonin for prevention of delirium in critically ill patients: a protocol for a multicentre, randomised, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Central Nervous System Depressants; Critical Illness; Delirium; Female; Hum | 2017 |
Observation and analysis of clinical efficacy of melatonin on AOPP-induced delirium patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Delirium; Female; Humans; Male; Melatonin; Middle Aged; Orga | 2018 |
Melatonin and Sleep in Preventing Hospitalized Delirium: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antioxidants; California; Delirium; Double-Blind Method; Female; Hospitaliz | 2018 |
Barriers to and facilitators of participation of older adults in a placebo-controlled randomized clinical trial.
Topics: Aged; Aged, 80 and over; Attitude to Health; Caregivers; Chronobiology Disorders; Comprehension; Del | 2013 |
Tryptophan supplementation and postoperative delirium--a randomized controlled trial.
Topics: Aged; Antidepressive Agents, Second-Generation; Delirium; Double-Blind Method; Elective Surgical Pro | 2014 |
Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Delirium; Double-Blind Method; Female; Frac | 2014 |
In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration.
Topics: Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Delirium; Electrocardiography; Female; Halo | 2015 |
Delirium and Circadian Rhythm of Melatonin During Weaning From Mechanical Ventilation: An Ancillary Study of a Weaning Trial.
Topics: Aged; Ancillary Services, Hospital; Circadian Rhythm; Delirium; Female; Follow-Up Studies; Humans; I | 2015 |
The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial.
Topics: Aged; Cardiac Surgical Procedures; Data Interpretation, Statistical; Delirium; Double-Blind Method; | 2016 |
Psychometric evaluation of the DMSS-4 in a cohort of elderly post-operative hip fracture patients with delirium.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Cognition; Delirium; Double-Blind Metho | 2016 |
Moderate dose melatonin for the abatement and treatment of delirium in elderly general medical inpatients: study protocol of a placebo controlled, randomised, double blind trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Dose-Re | 2016 |
Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial.
Topics: Administration, Oral; Clinical Protocols; Cost-Benefit Analysis; Critical Care; Delirium; Double-Bli | 2017 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Central Nervous System Depressants; Delirium; Double-Blind M | 2011 |
The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial.
Topics: Aged; Delirium; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Male; Melaton | 2011 |
36 other studies available for melatonin and Delirium
| Article | Year |
|---|---|
Relationship among melatonin, postoperative delirium, and postoperative cognitive dysfunction.
Topics: Cognition Disorders; Delirium; Humans; Incidence; Melatonin; Postoperative Cognitive Complications | 2021 |
Melatonin Administration Patterns for Pediatric Inpatients in a Tertiary Children's Hospital.
Topics: Adult; Child; Delirium; Humans; Inpatients; Intensive Care Units; Melatonin; Retrospective Studies; | 2021 |
Melatonin in ICU delirium: shining light on the hormone of darkness.
Topics: Darkness; Delirium; Humans; Intensive Care Units; Melatonin | 2022 |
Melatonin for the prevention of postoperative delirium in older adults: a protocol for a systematic review and meta-analysis.
Topics: Aged; Delirium; Humans; Incidence; Melatonin; Meta-Analysis as Topic; Review Literature as Topic; Sy | 2022 |
[Sundowning of the elderly person].
Topics: Aged; Circadian Rhythm; Delirium; Diagnosis, Differential; Existentialism; Humans; Melatonin | 2023 |
Assessment of melatonergics in prevention of delirium in critically ill patients: A protocol for systematic review and meta-analysis.
Topics: Critical Illness; Delirium; Humans; Intensive Care Units; Length of Stay; Melatonin; Meta-Analysis a | 2020 |
Relation of serum melatonin levels to postoperative delirium in older patients undergoing major abdominal surgery.
Topics: Abdomen; Age Factors; Aged; Biomarkers; Critical Care; Delirium; Female; Humans; Male; Melatonin; Po | 2020 |
Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients?
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Delirium; Humans; Melatonin; Pandemics; Pneumonia | 2020 |
Delirium, sleep, COVID-19 and melatonin.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Delirium; Humans; Melatonin; Pandemics; Pneumonia | 2020 |
Reply to 'Delirium, sleep, COVID-19 and melatonin'.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Delirium; Humans; Melatonin; Pandemics; Pneumonia | 2020 |
Effects of general versus regional anaesthesia on circadian melatonin rhythm and its association with postoperative delirium in elderly patients undergoing hip fracture surgery: study protocol for a prospective cohort clinical trial.
Topics: Aged; Anesthesia, Conduction; Circadian Rhythm; Delirium; Hip Fractures; Humans; Melatonin; Postoper | 2021 |
Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis.
Topics: Brain Ischemia; Delirium; Humans; Ischemic Stroke; Melatonin; Propensity Score; Prospective Studies; | 2021 |
Evaluation of Delirium in Critically Ill Patients Prescribed Melatonin or Ramelteon.
Topics: Critical Illness; Delirium; Humans; Hypnotics and Sedatives; Indenes; Intensive Care Units; Melatoni | 2021 |
Pediatric COVID-19 Delirium: Case Report of 2 Adolescents.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; COVID-19; Delirium; Drug The | 2021 |
Plasma melatonin levels in hip fracture patients with and without delirium: A confirmation study.
Topics: Aged; Aged, 80 and over; Chromatography, Liquid; Circadian Rhythm; Cognition Disorders; Delirium; Fe | 2017 |
Role of Ramelteon in Reduction of As-Needed Antipsychotics in Elderly Patients with Delirium in a General Hospital Setting.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Hospitals, General; Humans; Inciden | 2017 |
Delirium associated with only one dose of zopiclone in an older adult.
Topics: Aged, 80 and over; Antioxidants; Azabicyclo Compounds; Delirium; Female; Humans; Hypnotics and Sedat | 2018 |
Pharmacologic Treatment of Intensive Care Unit Delirium and the Impact on Duration of Delirium, Length of Intensive Care Unit Stay, Length of Hospitalization, and 28-Day Mortality.
Topics: Aged; Antipsychotic Agents; Delirium; Female; Hospital Mortality; Humans; Intensive Care Units; Kapl | 2018 |
Effectiveness of Melatonin for the Prevention of Intensive Care Unit Delirium.
Topics: Adult; Aged; Cohort Studies; Critical Illness; Delirium; Female; Humans; Intensive Care Units; Lengt | 2019 |
Melatonin for sundown syndrome and delirium in dementia: is it effective?
Topics: Aged, 80 and over; Alzheimer Disease; Central Nervous System Depressants; Delirium; Dose-Response Re | 2013 |
Effectiveness of melatonin for sundown syndrome and delirium.
Topics: Alzheimer Disease; Delirium; Humans; Male; Melatonin | 2014 |
[Research of 24-hour dynamic sleep monitoring and melatonin changes in patients with delirium in intensive care unit].
Topics: Biomedical Research; Case-Control Studies; Delirium; Humans; Intensive Care Units; Melatonin; Polyso | 2014 |
The diurnal profile of melatonin during delirium in elderly patients--preliminary results.
Topics: Aged; Aged, 80 and over; Circadian Rhythm; Comorbidity; Delirium; Female; Hospitalization; Hospitals | 2015 |
Melatonin Supplementation to Prevent Delirium in Hospitalized Elderly Patients.
Topics: Aged; Central Nervous System Depressants; Delirium; Geriatric Assessment; Hospitalization; Humans; I | 2016 |
Melatonin and melatonin agonists to prevent and treat delirium in critical illness: a systematic review protocol.
Topics: Critical Care; Critical Illness; Delirium; Humans; Hypnotics and Sedatives; Melatonin; Research Desi | 2016 |
Pharmacological interventions for delirium in intensive care patients: a protocol for an overview of reviews.
Topics: Critical Care; Critical Illness; Delirium; Humans; Hypnotics and Sedatives; Melatonin; Meta-Analysis | 2016 |
Preoperative CSF Melatonin Concentrations and the Occurrence of Delirium in Older Hip Fracture Patients: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Circadian Rhythm; Delirium; Female; Hip Fractures; Humans; Male; Melatonin; | 2016 |
Melatonin and postoperative delirium: a possible link?
Topics: Alcohol Withdrawal Delirium; Anesthesia Recovery Period; Delayed-Action Preparations; Delirium; Huma | 2010 |
[Delirium, insomnia in hospitalization and ramelteon].
Topics: Delirium; Hospitalization; Humans; Indenes; Melatonin; Sleep Initiation and Maintenance Disorders | 2012 |
Marked improvement in delirium with ramelteon: five case reports.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Circadian Rhythm; Delirium; Female; Humans; Indenes; Mal | 2012 |
Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium.
Topics: Aged; APACHE; Chi-Square Distribution; Comorbidity; Critical Illness; Delirium; Female; Humans; Inte | 2013 |
The relation between the clinical subtypes of delirium and the urinary level of 6-SMT.
Topics: Aged; Aged, 80 and over; Comorbidity; Delirium; Female; Geriatric Assessment; Humans; International | 2003 |
Postoperative delirium: the tryptophan dyregulation model.
Topics: Aged; Aged, 80 and over; Aging; Brain; Delirium; Humans; Melatonin; Models, Neurological; Postoperat | 2004 |
Postoperative delirium, plasma melatonin, and light.
Topics: Circadian Rhythm; Delirium; Humans; Light; Melatonin; Postoperative Complications | 2001 |
Postoperative delirium and melatonin levels in elderly patients.
Topics: Abdomen; Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Melatonin; Postoperative Complicat | 2001 |
Postoperative delirium and melatonin levels in elderly patients.
Topics: Abdomen; Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Melatonin; Postoperative Complicat | 2001 |
Postoperative delirium and melatonin levels in elderly patients.
Topics: Abdomen; Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Melatonin; Postoperative Complicat | 2001 |
Postoperative delirium and melatonin levels in elderly patients.
Topics: Abdomen; Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Melatonin; Postoperative Complicat | 2001 |
Melatonin for treatment and prevention of postoperative delirium.
Topics: Aged; Delirium; Humans; Male; Melatonin; Middle Aged; Postoperative Complications | 2002 |